Effect of Rosuvastatin Therapy in Patients With Stable Chronic Obstructive Pulmonary Disease

Phase 2

Completed

• Conditions: Chronic Obstructive Pulmonary Disease (COPD)
• Interventions: Drug: Placebo; Drug: Rosuvastatin

• Registration Number: NCT00929734
• Lead Sponsor: University Hospital, Akershus

Brief Summary

The purpose of this study is to investigate whether rosuvastatin improves measures of endothelial function, decreases measures of inflammation, and improves pulmonary function in patients with stable chronic obstructive pulmonary disease.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2009-06-26
• Study First Submitted QC: 2009-06-26
• Study First Posted: 2009-06-29
• Study Start: 2010-03
• Primary Completion: 2014-01
• Study Completion: 2014-01
• Results First Submitted: 2015-07-09
• Status Verified: 2015-09
• Results First Submitted QC: 2015-09-07
• Last Update Submitted: 2015-09-07
• Results First Posted: 2015-10-08
• Last Update Posted: 2015-10-08

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 99

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Placebo	Placebo	-
Rosuvastatin	Rosuvastatin	-

Primary Outcome Measures

Name	Time	Method
Relative Change in Reactive Hyperemia Index (RHI)	Baseline to 3 months	Endothelial function assessed with peripheral arterial tonometry, expressed as the reactive hyperemia index (RHI) as a marker for subclinical atherosclerosis and future cardiovascular risk assessment.

Secondary Outcome Measures

Name	Time	Method
Relative Change in FEV1	Baseline to 3 months
Relative Change in High-sensitivity C-reactive Protein	Baseline to 3 months
Relative Change in Interleukin 6	Baseline to 3 months

Trial Locations

Locations (1)

Akershus University Hospital; 🇳🇴 Lørenskog, Akershus, Norway